E.2. Afatinib (Gilotrif™, Giotrif®)
The
commercial product of afatinib (Fig. 1.13) is an orally administered inhibitor
of the ErbB family of tyrosine kinases. Afatinib also inhibits human epidermal growth
factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR). The
inhibition is through the formation of a C-S covalent bond between afatinib and
a cysteine in EGFR.
Fig. 1.13 Afatinib
Afatinib (Fig. 1.13) was first indicated for
treating non-small cell lung cancer. In addition, it has been reported that afatinib may be useful to treat
other cancers.
© Jiajiu Shaw, 2019
Disclaimer: This blog is written solely for informational purposes. It does not constitute the practice of any medical, nursing or other medical professional health care advice, diagnosis, or treatment. All contents posted are extracted from the book, "SIDE EFFECTS OF CHEMOTHERAPY AND RADIOTHERAPY", prepared by Dr. Jiajiu Shaw, Dr. Frederick Valeriote, and Dr. Ben Chen.
